Skip to content

A prospective double blind randomised controlled study to evaluate the immunological benefits and clinical effects of an elimination diet using an amino acid formula (AAF) with an added pre-probiotic blend in infants with Cow's Milk Allergy (CMA).

A prospective double blind randomised controlled study to evaluate the immunological benefits and clinical effects of an elimination diet using an amino acid formula (AAF) with an added pre-probiotic blend in infants with Cow's Milk Allergy (CMA).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28608
Enrollment
170
Registered
2012-11-28
Start date
2013-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infants with Cow's Milk Allergy

Interventions

Duration of intervention: 12 months. Intervention group: AAF with prebiotics and probiotics (synbiotics) formulation. Control group: AAF without synbiotics.

Sponsors

Danone Research – Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Infants 0.1kU/L and/or Skin Prick Testing (SPT) wheal size >= 3mm before entering the study. The diagnosis of IgE mediated CMA should be confirmed by cow's milk challenge or history of an anaphylaxis reaction; 3. Infants expected to consume the required amount of formula during the study intervention.

Exclusion criteria

Exclusion criteria: 1. Infants in non-Asian countries less than 2500 g at birth. Infants in Asian countries less than 2250 g at birth; 2. Infants less than 37 weeks gestation and requires specific premature formula at the time of study entry; 3. Infants with severe concurrent illness; 4. Use of anti- histamines in the 4 days preceding study entry; 5. Use of systemic corticosteroids in the 4 weeks preceding study entry and not willing to exclude corticosteroids in the 4 weeks preceding each study visit; 6. Use of probiotic bacteria or probiotic containing drinks/supplements; 7. Use of systemic antibiotics or anti-mycotic drugs 4 weeks preceding study entry; 8. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements; 9. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Design outcomes

Primary

MeasureTime frame
The primary study endpoint is the proportion of the infants who develop oral tolerance to cow’s milk.

Secondary

MeasureTime frame
1. Maturation of the GI (immune) system in cow’s milk allergic infants; 2. Effectiveness of the study product in the dietary management of CMA/food allergy; 3. Frequency of other allergies (non-food).

Contacts

Public ContactNutricia Research

Nutricia Research - Advanced Medical Nutrition;

e-mail: barbara.mourmans@nutricia.comTelephone: +31 (0)30 209 5000

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)